Search
Now showing items 41-50 of 205
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results
(2000)
Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: A randomized phase III study conducted by the hellenic cooperative oncology group
(1999)
Background: Randomized studies have shown that postoperative chemotherapy with or without radiation therapy (RT) improved local control and survival of patients with stages II or III rectal cancer. However, the optimal ...
Five tumor markers in lung cancer: Significance of total and>-Bound sialic acid
(1991)
Total sialic acid (TSA) and > sialic acid (LSA) were evaluated in comparison to carcinoembryonic antigen (CEA) and ferritin and neuron specific enolase (NSE) in 152 untreated patients with primary lung cancer, 107 benign ...
Measuring Altruistic and Solidaristic Orientations Toward Others among People Who Inject Drugs
(2015)
The altruism and/or solidarity of people who inject drugs helps protect sex and drug partners from HIV. Research has been hindered by lack of measures. We developed and administered scales to assess them to 300 people who ...
Personality variables as predictors of early non-metastatic colorectal cancer patients' psychological distress and health-related quality of life: A one-year prospective study
(2011)
Objective: We aimed to assess the course of early non-metastatic colorectal cancer patients' psychological distress and health-related quality of life (HRQOL) and to identify relevant clinical and psychological predictors ...
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
(1997)
A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
Successful treatment of human immunodeficiency virus-related castleman's disease: A case report and literature review
(2003)
Multicentric Castleman's disease is increasingly recognized as an aggressive illness with a rapidly fatal outcome in human immunodeficiency virus (HIV)-infected patients. In the absence of optimal therapy, various therapeutic ...
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
(2002)
Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...
Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: To target or not to target?
(2007)
Introduction: Epidermal growth factor receptor (EGFR) signalling contributes to malignant transformation and survival. We studied molecular predictors of benefit from EGFR-modulating therapies in patients with cancer of ...